IDELVION(R) Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing

European Medicines Agency Approves 21-Day Dosing Intervals for Adult Haemophilia B Patients HATTERSHEIM, Germany, July 3, 2020 -- (Healthcare Sales & Marketing Network) -- Global biotherapeutics leader CSL Behring announced today that the European Medi... Biopharmaceuticals, Regulatory CSL Behring, IDELVION , albutrepenonacog alfa, Factor IX, haemophilia B
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news